The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

Annibali, Ombretta; Hohaus, Stefan; Marchesi, Francesco; Rocco, Alice Di; Tomarchio, Valeria; Napoli, Arianna Di; Pelliccia, Sveva; Battistini, Roberta; Borza, Paola Anticoli; Abruzzese, Elisabetta; Cenfra, Natalia; Andriani, Alessandro; Tesei, Cristiano; Alma, Eleonora; Palombi, Francesca; Pupo, Livio; Petrucci, Luigi; Becilli, Marco; Maiolo, Elena; Bellesi, Silvia; Cuccaro, Annarosa; D’Alo’, Francesco; Cox, Maria Christina

doi:10.1080/10428194.2019.1633628

Cited by 14 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…107 It was revised in 2006. 106 Annibali et al 45 Italy 505 Patients with NLR<3.5 had higher 4-year OS probability than patients with NLR ratio ≥3.5 (86% vs 64%) and higher 4-year EFS probability than patients with NLR ratio ≥3.5 (76% vs 48%). system.…”

Section: Nlr and Mlr In Multiple Myelomamentioning

confidence: 98%

“…Feng et al 44 proved that low absolute lymphocyte count (ALC) is an adverse prognostic sign in DLBCL. 44 Annibali et al 45 revealed that NLR is an independent prognostic factor and it can help to separate patients with low/intermediate IPI (IPI<3). 45 In contrast to the studies mentioned above, Azuma et al 46 failed to reveal predictive value of NLR.…”

Section: Leukocytes Involvement In Tumor Pathogenesismentioning

confidence: 99%

See 1 more Smart Citation

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

Stefaniuk¹,

Szymczyk²,

Podhorecka³

2020

CMAR

View full text Add to dashboard Cite

Despite the presence of many hematological prognostic indexes, clinical course and overall survival are often highly variable even within the same patient subgroup. Recent studies suggest that simple, cost-effective, low-risk tests such as neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR) may be used to evaluate the prognosis. Their role has been well confirmed in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and multiple myeloma (MM), but until now the prognostic significance of NLR and LMR in leukemias has not been widely reported. In this article, we analyze the literature data on prognostic value of NLR and LMR in haematological malignancies in the context of classic prognostic factors and clinical course.

show abstract

Section: Nlr and Mlr In Multiple Myelomamentioning

confidence: 98%

Section: Leukocytes Involvement In Tumor Pathogenesismentioning

confidence: 99%

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

Stefaniuk¹,

Szymczyk²,

Podhorecka³

2020

CMAR

View full text Add to dashboard Cite

show abstract

“…The complete blood counts (CBCs) such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have shown their values in predicting the prognosis of cancers. Amounts of evidences have confirmed the values of CBCs in predicting prognoses of gastric cancer (13), breast cancer (14), liver cancer (15) and lymphoma (16). However, little is known about the prognostic value of CBCs in PCNSL.…”

Section: Introductionmentioning

confidence: 99%

Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma

et al. 2021

View full text Add to dashboard Cite

BackgroundPrimary central nervous system lymphoma (PCNSL), an aggressive type of non-Hodgkin lymphoma, has a poor prognosis. Currently available prognostic scoring systems are inadequate. We therefore aimed to investigate the predictive values of complete blood counts (CBCs) in PCNSL.Materials and MethodsThe cohort of this retrospective study comprised 73 PCNSL patients. The predictive values of selected CBCs, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune inflammation index (SII), and systemic inflammation response index (SIRI), were analyzed.ResultsAges and Memorial Sloan Kettering Cancer Center (MSKCC) scores of PCNSL patients correlated with NLR, PLR, and SII values (p <0.05). Both age and MSKCC scores correlated with inferior progression-free survival (PFS) and overall survival (OS) (p <0.05). High NLR, PLR, SII, and SIRI were significant predictors of shorter PFS and OS (p <0.05). NLR, PLR, SII, and SIRI were integrated to generate a “CBC score” model that accurately stratified PCNSL patients into three risk groups. The median PFS for low-risk, intermediate-risk, and high-risk groups were 24 ((12.458–35.542), 17 (10.626–23.374), and 9 (8.893–19.107) months, respectively (p = 0.011), and the median OS were 33 (19.175–46.825), 18 (16.368–19.632), and 9 (6.521–11.479) months, respectively (p = 0.008). Multivariate Cox regression model showed that MSKCC score (hazard ratio (HR) = 3.791, p <0.001), PLR (HR = 1.003, p = 0.013), and CBC score (HR = 1.873, p = 0.011) were independent predictors for PFS, whereas MSKCC score (HR = 4.128, p <0.001), PLR (HR = 1.003, p = 0.005), and CBC score (HR = 1.907, p = 0.004) were independent predictors for OS.ConclusionThe CBC score model may be a promising predictive system for PCNSL patients.

show abstract

“…Meanwhile, a meta-analysis revealed that high PLR was related to poor tumor behavior and poor OS with 1931 individuals, and the PLR might be an effective factor of poor prognosis for patients with DLBCL ( 28 ). A study of 505 patients proved that NLR may be a useful prognostic marker in OS and could predict the progression in patients with DLBCL ( 11 ). A recent meta-analysis revealed that the NLR was associated with worse OS and regarded as an inexpensive prognostic factor with 2297 patients with DLBCL ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

“…Peripheral blood counts which in some degree reflect inflammation status are closely related to the progress of cancers ( 9 , 10 ). Numerous studies published in recent years have demonstrated that inflammation indicators such as pretreatment neutrophil-lymphocyte ratio (NLR) ( 11 ) and platelet-lymphocyte ratio (PLR) ( 12 ) play crucial roles in influencing the outcomes of the DLBCL patients. Moreover, compared with molecular genetic markers, blood biomarkers are cheaper and easier to obtain.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

et al. 2021

View full text Add to dashboard Cite

ObjectiveThe systemic immune-inflammation index (SII) based on neutrophil, platelet and lymphocyte counts, is a prognostic biomarker in some solid cancers. However, the prognostic value of SII has not yet been validated. This study was to evaluate the role of SII in predicting survival for patients with diffuse large B cell lymphoma (DLBCL).MethodsWe retrospectively investigated 224 patients with DLBCL between August 2005 and October 2018. Kaplan–Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.ResultsIn the ROC curve analysis, SII had the highest AUC and was more accurate as a prognostic factor. Patients with higher SII tended to have higher level of LDH, more advanced stage, poor PS, and high IPI score compared with low SII group. In univariate analyses, SII, PLR and NLR were all prognostic for progression-free survival and overall survival. Moreover, only SII, older age, HBSAg-positive and IPI were the independent prognostic factors for patients in multivariate analysis. The nomogram based on SII, older age, HBSAg status and IPI showed accurate prognostic ability for predicting 3-years and 5-years survival rates (c-index, 0.791) compared to the IPI alone (c-index, 0.716).ConclusionSII was a powerful tool for predicting outcome in patients with DLBCL. It might assist the separation of high-risk patients among patients with the same IPI.

show abstract

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

Cited by 14 publications

References 25 publications

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma

Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About